To bring quality cancer treatment closer to patients, India’s leading MedTech brand is joining forces with the unique technology-led platform
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028
SEEDS is a mnemonic for Shun Tobacco, Eat Correctly, Exercise Regularly, Dump obesity and excess alcohol, and Stay vigilant about your family history aims at making more and more people aware about the tenets of cancer prevention
For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions
On the day dedicated to the battle against the deadly disease – took to reaching the public of Pune to understand that cancer can be prevented and even reversed with the help of adequate testing
Subscribe To Our Newsletter & Stay Updated
